[1] |
Jeha S, Pei D, Choi J, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16[J]. J Clin Oncol, 2019, 37(35): 3377-3391.
doi: 10.1200/JCO.19.01692
pmid: 31657981
|
[2] |
Taillibert S, Le Rhun E, Chamberlain MC. Chemotherapy-related neurotoxicity[J]. Curr Neurol Neurosci Rep, 2016, 16(9): 81.
|
[3] |
Gibson EM, Nagaraja S, Ocampo A, et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment[J]. Cell, 2019, 176(1-2): 43-55.
doi: S0092-8674(18)31405-3
pmid: 30528430
|
[4] |
Lenfant C, Greiner N, Duprez T. Cytarabine-induced encephalitis[J]. J Belg Soc Radiol, 2021, 105(1): 46.
doi: 10.5334/jbsr.2492
pmid: 34611580
|
[5] |
Newey CR, Chandrasekaran PN, Mohebbi MR. Posterior reversible encephalopathy syndrome after high-dose cytarabine in acute myelogenous leukemia[J]. Neurol India, 2017, 65(1): 220.
doi: 10.4103/0028-3886.198171
pmid: 28084289
|
[6] |
Abaji R, Krajinovic M. Pharmacogenetics of asparaginase in acute lymphoblastic leukemia[J]. Cancer Drug Resist, 2019, 2(2): 242-255.
doi: 10.20517/cdr.2018.24
pmid: 35582721
|
[7] |
Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy[J]. Blood Rev, 2015, 29(2): 93-100.
doi: 10.1016/j.blre.2014.09.012
pmid: 25445718
|
[8] |
吴晔. 儿童脑白质病变的识别及诊断[J]. 北京医学, 2018, 40(7): 614-615.
|
|
Wu Y. Identification and diagnosis of white matter lesions in children[J]. Beijing Yikue, 2018, 40(7): 614-615.
|
[9] |
中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9): 641-644.
|
|
Hematology Group of pediatric Society of Chinese Medical Association, Editorial Board of Chinese Journal of Pediatrics. Recommendations for diagnosis and treatment of childhood acute lymphoblastic leukemia (the fourth revision)[J]. Zhonghua Erke Zazhi, 2014, 52(9): 641-644.
|
[10] |
Conklin HM, Krull KR, Reddick WE, et al. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia[J]. J Natl Cancer Inst, 2012, 104(18): 1386-1395.
pmid: 22927505
|
[11] |
Cao SC, Legerstee JS, van Bellinghen M, et al. Effect of chemotherapy (with and without radiotherapy) on the intelligence of children and adolescents treated for acute lymphoblastic leukemia; a meta-analysis[J]. Psychooncology, 2023, 32(4): 492-505.
|
[12] |
Jacola LM, Conklin HM, Krull KR, et al. The impact of intensified CNS-directed therapy on neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated without cranial irradiation[J]. J Clin Oncol, 2022, 40(36): 4218-4227.
|
[13] |
Krull KR, Cheung YT, Liu W, et al. Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 2016, 34(22): 2644-2653.
doi: 10.1200/JCO.2015.65.4574
pmid: 27269941
|
[14] |
Śliwa-Tytko P, Kaczmarska A, Lejman M, et al. Neurotoxicity associated with treatment of acute lymphoblastic leukemia chemotherapy and immunotherapy[J]. Int J Mol Sci, 2022, 23(10): 5515.
|
[15] |
Sainz de la Maza Cantero S, Jiménez Martín A, de Felipe Mimbrera A, et al. Cerebellar toxicity due to cytarabine: a series of 4 cases[J]. Neurologia, 2016, 31(7): 491-492.
|
[16] |
Drachtman RA, Cole PD, Golden CB, et al. Dex-tromethorphan is effective in the treatment of subacute methotrexate neurotoxicity[J]. Pediatr Hematol Oncol, 2002, 19(5): 319-327.
pmid: 12078863
|
[17] |
Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency[J]. J Clin Oncol, 1997, 15(2): 833-839.
pmid: 9053511
|
[18] |
Partap S, Russo S, Esfahani B, et al. A review of chronic leukoencephalopathy among survivors of childhood cancer[J]. Pediatr Neurol, 2019, 101: 2-10.
doi: S0887-8994(18)31330-4
pmid: 31047756
|
[19] |
Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients[J]. Blood, 2006, 108(7): 2216-2222.
doi: 10.1182/blood-2006-04-015511
pmid: 16804111
|
[20] |
Kieslich M, Porto L, Lanfermann H, et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia[J]. J Pediatr Hematol Oncol, 2003, 25(6): 484-487.
pmid: 12794528
|
[21] |
Goyal G, Bhatt VR. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia[J]. Future Oncol, 2015, 11(17): 2459-2470.
doi: 10.2217/fon.15.114
pmid: 26274336
|
[22] |
Alessi I, Caroleo AM, de Palma L, et al. Short and long-term toxicity in pediatric cancer treatment: central nervous system damage[J]. Cancers (Basel), 2022, 14(6): 1540.
|
[23] |
Kim KH, Park M, Park EY, et al. Disseminating necrotizing leukoencephalopathy associated with intra-CSF methotrexate chemotherapy: a retrospective observational study[J]. Neurology, 2024, 102(5): e209167.
|